Effects of Heme Arginate in Healthy Male Subjects

Inclusion Criteria: * Signed informed consent prior to any study-mandated procedure. * Male aged between 18 and 45 years (inclusive) at screening. * No clinically significant findings on the physical examination at screening. * Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) at screening. * 12-lead ECG without clinically relevant abnormalities at screening. * Hematology, clinical chemistry, and urinalysis test results not deviating from the normal range to a clinically relevant extent at screening. * Negative results from urine drug screen at screening. * Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study. Exclusion Criteria: * Known hypersensitivity to the study drug or any excipients of the drug formulation. * Treatment with another investigational drug within 3 months prior to screening. * History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. * History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs. * Smoking within the last 3 months prior to screening. * Previous treatment with any prescribed or OTC medications (including herbal medicines such as St John's Wort) within 2 weeks prior to screening. * Loss of 250 ml or more of blood within 3 months prior to screening. * Positive results from the hepatitis serology, except for vaccinated subjects, at screening. * Positive results from the HIV serology at screening. * Presumed non-compliance. * Legal incapacity or limited legal capacity at screening.